Do you know the new treatment that shows significant improvement in metastasis-free survival and time to symptomatic progression among men with non-metastatic castration-resistant prostate cancer?

News

At the Philadelphia Prostate Consensus Conference, a panel of experts addressed genetic counseling and testing, screening, and management in patients with prostate cancer.
A new clinical-genomic risk group classification may accurately identify patients at low, intermediate, and high risk for metastasis in localized prostate cancer.
Biopsies every 2 years, instead of annually, seem to be "an acceptable alternative" for acute surveillance of low-risk prostate cancer, according to a comparative analysis.
Positron emission tomography (PET)-based molecular imaging biomarkers may predict therapeutic response and survival in patients with metastatic castration-resistant prostate cancer (mCRPC).

Research in Review

Men diagnosed with prostate cancer may become distressed and consequently choose unnecessarily aggressive treatment options, according to a new study published in the Journal of Oncology.

-----

Related Content

Read More

Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone with prednisone alone, according to findings from a new trial.

-----

Related Content

Read More

Increase in metastatic prostate cancer in older men has a definitive correlation with changes in prostate cancer screening guidelines recommending against prostate-specific antigen (PSA) testing, according to research published in JAMA Oncology.

-----

Related Content

Read More

Using testosterone-lowering drugs to treat prostate cancer may make men twice as likely to develop dementia within five years as patients whose testosterone levels were not tampered with, according to a retrospective study.

Read More

Subscribe to Prostate Cancer